for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare

BRIEF-Beigene Presents Updated Results From Phase 3 Trial Of Zanubrutinib vs Ibrutinib In Patients With Waldenström’S Macroglobulinemia

May 29 (Reuters) - Beigene Ltd:

* BEIGENE PRESENTS UPDATED HEAD TO HEAD RESULTS FROM PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS. IBRUTINIB IN PATIENTS WITH WALDENSTRÖM’S MACROGLOBULINEMIA AT THE 2020 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) VIRTUAL SCIENTIFIC PROGRAM Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up